- Home
- RVP vs CMMB Comparison
RVP vs CMMB Comparison
Compare RVP & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVP
- CMMB
- Stock Information
- Founded
- RVP 1994
- CMMB 2004
- Country
- RVP United States
- CMMB Israel
- Employees
- RVP N/A
- CMMB N/A
- Industry
- RVP Medical/Dental Instruments
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- RVP Health Care
- CMMB Health Care
- Exchange
- RVP Nasdaq
- CMMB Nasdaq
- Market Cap
- RVP 25.1M
- CMMB 22.0M
- IPO Year
- RVP 2001
- CMMB N/A
- Fundamental
- Price
- RVP $0.82
- CMMB $2.83
- Analyst Decision
- RVP
- CMMB Strong Buy
- Analyst Count
- RVP 0
- CMMB 2
- Target Price
- RVP N/A
- CMMB $26.50
- AVG Volume (30 Days)
- RVP 77.0K
- CMMB 141.5K
- Earning Date
- RVP 11-13-2025
- CMMB 11-13-2025
- Dividend Yield
- RVP N/A
- CMMB N/A
- EPS Growth
- RVP N/A
- CMMB N/A
- EPS
- RVP N/A
- CMMB N/A
- Revenue
- RVP $38,161,712.00
- CMMB N/A
- Revenue This Year
- RVP N/A
- CMMB N/A
- Revenue Next Year
- RVP N/A
- CMMB N/A
- P/E Ratio
- RVP N/A
- CMMB N/A
- Revenue Growth
- RVP N/A
- CMMB N/A
- 52 Week Low
- RVP $0.56
- CMMB $2.71
- 52 Week High
- RVP $0.94
- CMMB $9.84
- Technical
- Relative Strength Index (RSI)
- RVP 57.25
- CMMB 21.60
- Support Level
- RVP $0.79
- CMMB $2.96
- Resistance Level
- RVP $0.83
- CMMB $3.09
- Average True Range (ATR)
- RVP 0.03
- CMMB 0.21
- MACD
- RVP -0.00
- CMMB 0.00
- Stochastic Oscillator
- RVP 55.44
- CMMB 11.26
About RVP Retractable Technologies Inc.
Retractable Technologies Inc designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession. The company's products are the VanishPoint 0.5mL insulin syringe; 1mL tuberculin, insulin, and allergy antigen syringes; 0.5mL, 1mL, 2mL, 3mL, 5mL, and 10mL syringes; the small diameter tube adapter; the blood collection tube holder; the allergy tray; the IV safety catheter; the Patient Safe syringes; the Patient Safe Luer Cap; the VanishPoint Blood Collection Set; and the EasyPoint needle, as well as a standard 3mL syringe packaged with an EasyPoint needle. The company also sells VanishPoint autodisable syringes in the international market in addition to the Company's other products.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.